 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5390 News |  |
| «12...58596061626364656667686970 |
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer (clinicaltrials.gov) - Sep 5, 2013
P2, N=88, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer (clinicaltrials.gov) - Sep 3, 2013
P2, N=64, Recruiting, Sponsor: Lajos Pusztai
Not yet recruiting --> Recruiting
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: SAFE-HEaRt: Cardiac Safety Study in Patients With HER2 + Breast Cancer (clinicaltrials.gov) - Aug 19, 2013
P2, N=33, Recruiting, Sponsor: Washington Hospital Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- AST-301 / University of Washington, Aston Sci., EpiThany
New P1/2 trial, IO biomarker, Metastases: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Aug 12, 2013
P1/2, N=30, Recruiting, Sponsor: University of Washington
- | lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial, Combination therapy, Metastases: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Aug 5, 2013
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Aug 5, 2013
P1, N=40, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Jul 29, 2013
P2, N=68, Recruiting, Sponsor: Dana-Farber Cancer Institute
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Metastases: A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 28, 2013
P1, N=107, Completed, Sponsor: Genentech
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Jul 23, 2013
P2, N=45, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: EORTC-75111-10114: Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 (clinicaltrials.gov) - Jul 23, 2013
P2, N=80, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Combination therapy, Metastases: PERNETTA: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (clinicaltrials.gov) - Jul 22, 2013
P2, N=208, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Not yet recruiting --> Recruiting Initiation date: Apr 2013 --> Jul 2013
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: SAFE-HEaRt: Cardiac Safety Study in Patients With HER2 + Breast Cancer (clinicaltrials.gov) - Jul 18, 2013
P2, N=33, Recruiting, Sponsor: Washington Hospital Center
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: NSABP Biospecimen Discovery Project (clinicaltrials.gov) - Jul 17, 2013
P=N/A, N=50, Recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
Initiation date: Apr 2013 --> Jul 2013 Not yet recruiting --> Recruiting
- Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date: SOLTI-Opti-HER: Study of Neoadjuvant Myocet (clinicaltrials.gov) - Jul 2, 2013
P2, N=83, Active, not recruiting, Sponsor: SOLTI Breast Cancer Research Group
Not yet recruiting --> Recruiting Initiation date: Nov 2012 --> Jun 2013
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial: Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib (clinicaltrials.gov) - Jun 10, 2013
P1, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer (clinicaltrials.gov) - May 22, 2013
P2a, N=30, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Nov 2012 --> Jun 2013 Recruiting --> Active, not recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer (clinicaltrials.gov) - May 15, 2013
P2, N=64, Recruiting, Sponsor: Lajos Pusztai
- New P2 trial: Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (clinicaltrials.gov) - May 2, 2013
P2, N=20, Recruiting, Sponsor: Columbia University
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Metastases: A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 25, 2013
P1, N=107, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting N=74 --> 107
- | Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: PERNETTA: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (clinicaltrials.gov) - Apr 16, 2013
P2, N=208, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
- Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: PERNETTA: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (clinicaltrials.gov) - Apr 14, 2013
P2, N=208, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
N=74 --> 107 Not yet recruiting --> Recruiting
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (clinicaltrials.gov) - Mar 21, 2013
P2, N=220, Recruiting, Sponsor: West German Study Group
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial, Metastases: PETRA: Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (clinicaltrials.gov) - Mar 4, 2013
P1, N=30, Recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, BRCA Biomarker: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) - Feb 19, 2013
P2, N=30, Recruiting, Sponsor: Dana-Farber Cancer Institute
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy, Metastases: JACOB: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (clinicaltrials.gov) - Jan 22, 2013
P3, N=780, Recruiting, Sponsor: Hoffmann-La Roche
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Combination therapy, Metastases: NeoSphere: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. (clinicaltrials.gov) - Jan 2, 2013
P2, N=417, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Initiation date: Jun 2006 --> Dec 2007
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Metastases: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Nov 19, 2012
P2, N=45, Recruiting, Sponsor: City of Hope Medical Center
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Combination therapy, Metastases: A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer (clinicaltrials.gov) - Sep 18, 2012
P2, N=95, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jun 2006 --> Dec 2007 N=9595 --> 95
- |||||||||| Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy: Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) (clinicaltrials.gov) - Sep 11, 2012
P3, N=184, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer (clinicaltrials.gov) - Aug 26, 2012
P2, N=95, Active, not recruiting, Sponsor: Hoffmann-La Roche
- | Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: SOLTI-Opti-HER: Study of Neoadjuvant Myocet (clinicaltrials.gov) - Aug 16, 2012
P2, N=83, Active, not recruiting, Sponsor: SOLTI Breast Cancer Research Group
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Combination therapy, Metastases: A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab (clinicaltrials.gov) - Jul 24, 2012
P1/2, N=67, Completed, Sponsor: Hoffmann-La Roche
N=9595 --> 95 Initiation date: Jan 2009 --> May 2009
- |||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab (clinicaltrials.gov) - Jul 18, 2012
P1/2, N=67, Completed, Sponsor: Hoffmann-La Roche
Initiation date: Jan 2009 --> May 2009 Active, not recruiting --> Completed
- ||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) (clinicaltrials.gov) - May 31, 2012
P3, N=1095, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Perjeta (pertuzumab) / Roche
Trial completion, FDG PET: PENGUIN: A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer (clinicaltrials.gov) - May 14, 2012
P2, N=41, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Metastases: EORTC-75111-10114: Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 (clinicaltrials.gov) - May 10, 2012
P2, N=80, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- || Perjeta (pertuzumab) / Roche
New P3 trial: Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) (clinicaltrials.gov) - Apr 22, 2012
P3, N=1200, Active, not recruiting, Sponsor: German Breast Group
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy, Metastases: PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (clinicaltrials.gov) - Apr 3, 2012
P3, N=1500, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (clinicaltrials.gov) - Mar 26, 2012
P2, N=213, Active, not recruiting, Sponsor: Hoffmann-La Roche
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - Mar 15, 2012
P2, N=250, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: TRYPHAENA: A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer (clinicaltrials.gov) - Mar 15, 2012
P2, N=225, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Metastases: Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab (clinicaltrials.gov) - Mar 6, 2012
P2, N=37, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| New P4 trial: MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (clinicaltrials.gov) - Dec 27, 2011
P4, N=226, Recruiting, Sponsor: Agendia
- |||| Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Metastases: Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression (clinicaltrials.gov) - Dec 21, 2011
P2, N=51, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - Dec 12, 2011
P2, N=250, Recruiting, Sponsor: Hoffmann-La Roche
- Perjeta (pertuzumab) / Roche
Enrollment change, Metastases: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors (clinicaltrials.gov) - Nov 8, 2011
P2, N=4, Terminated, Sponsor: Pamela L. Kunz
Active, not recruiting --> Completed N=40 --> 4
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2a trial, Combination therapy, Metastases: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer (clinicaltrials.gov) - Oct 25, 2011
P2a, N=30, Active, not recruiting, Sponsor: Hoffmann-La Roche